Floatz logo

Edotreotide

Neuroendocrine Neoplasm

British Columbia Cancer Agencyprotein_peptidePhase 3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
73/ 100

Competitive context

58 Active assets in the Neuroendocrine Neoplasm cohort.

Asset / SponsorPhaseRating
Fluorouracilum
ITM Solucin GmbH
Phase 3BB
Xaliplatin
ITM Solucin GmbH
Phase 3BB
Irinotecan
First Affiliated Hospital Xi'an Jiaotong University
Phase 4BB
Cabozantinib
Fox Chase Cancer Center
Phase 3BB
Everolimus
Exelixis
Phase 3BB

View all 50 →

Same molecule, other indications

Edotreotide is also rated in:

digestive system neuroendocrine neoplasmActive
B
Indicative · Phase 3
63 / 100
View asset →
neuroblastomaDormant
B
Indicative · Phase 2
60 / 100
View asset →
carcinoid tumorActive
B
Indicative · Phase 2
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →